 BRIDGEWATER, N.J., March 23, 2021 PRNewswire -- Insmed Incorporated Nasdaq:INSM, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Japans Ministry of Health, Labour and Welfare MHLW has approved ARIKAYCE amikacin liposome inhalation suspension for the treatment of patients with nontuberculous mycobacterial NTM lung disease caused by Mycobacterium avium complex MAC who did not sufficiently respond to prior treatment with a multidrug regimen MDR. 